Hajek R - Search Results

1

PD-1/PD-L1 inhibitors in multiple myeloma: The present and the future.

Jelinek T, Hajek R. Jelinek T, et al. Among authors: hajek r. Oncoimmunology. 2016 Nov 8;5(12):e1254856. doi: 10.1080/2162402X.2016.1254856. eCollection 2016. Oncoimmunology. 2016. PMID: 28123899 Free PMC article. Review.

2

The role of histone deacetylase inhibitors in patients with relapsed/refractory multiple myeloma.

Hajek R, Siegel D, Orlowski RZ, Ludwig H, Palumbo A, Dimopoulos M. Hajek R, et al. Leuk Lymphoma. 2014 Jan;55(1):11-8. doi: 10.3109/10428194.2013.797084. Epub 2013 Jun 12. Leuk Lymphoma. 2014. PMID: 23614765 Review.

3

Plasma cell leukemia: from biology to treatment.

Jelinek T, Kryukov F, Rihova L, Hajek R. Jelinek T, et al. Among authors: hajek r. Eur J Haematol. 2015 Jul;95(1):16-26. doi: 10.1111/ejh.12533. Epub 2015 Mar 16. Eur J Haematol. 2015. PMID: 25778450 Review.

4

Monoclonal antibodies - A new era in the treatment of multiple myeloma.

Jelinek T, Hajek R. Jelinek T, et al. Among authors: hajek r. Blood Rev. 2016 Mar;30(2):101-10. doi: 10.1016/j.blre.2015.08.004. Epub 2015 Aug 24. Blood Rev. 2016. PMID: 26362528 Review.

5

Cytogenetics in multiple myeloma patients progressing into extramedullary disease.

Besse L, Sedlarikova L, Greslikova H, Kupska R, Almasi M, Penka M, Jelinek T, Pour L, Adam Z, Kuglik P, Krejci M, Hajek R, Sevcikova S. Besse L, et al. Among authors: hajek r. Eur J Haematol. 2016 Jul;97(1):93-100. doi: 10.1111/ejh.12688. Epub 2015 Oct 19. Eur J Haematol. 2016. PMID: 26432667

6

Immunomodulatory drugs in AL amyloidosis.

Jelinek T, Kufova Z, Hajek R. Jelinek T, et al. Among authors: hajek r. Crit Rev Oncol Hematol. 2016 Mar;99:249-60. doi: 10.1016/j.critrevonc.2016.01.004. Epub 2016 Jan 15. Crit Rev Oncol Hematol. 2016. PMID: 26806146 Review.

7

Proteasome inhibitors in AL amyloidosis: focus on mechanism of action and clinical activity.

Jelinek T, Kryukova E, Kufova Z, Kryukov F, Hajek R. Jelinek T, et al. Among authors: hajek r. Hematol Oncol. 2017 Dec;35(4):408-419. doi: 10.1002/hon.2351. Epub 2016 Sep 20. Hematol Oncol. 2017. PMID: 27647123 Review.

8

[Daratumumab - Hope for Myeloma Patients, a Challenge for Clinical Laboratories].

Jelínek T, Kořístka M, Čermáková Z, Hájek R. Jelínek T, et al. Among authors: hajek r. Klin Onkol. 2017 Winter;30(1):13-19. doi: 10.14735/amko201713. Klin Onkol. 2017. PMID: 28185460 Review. Czech.

9

Biobanking strategy and sample preprocessing for integrative research in monoclonal gammopathies.

Ševčíková T, Growková K, Kufová Z, Filipová J, Vrublová P, Jelínek T, Kořístek Z, Kryukov F, Kryukova E, Hájek R. Ševčíková T, et al. Among authors: hajek r. J Clin Pathol. 2017 Oct;70(10):847-853. doi: 10.1136/jclinpath-2017-204329. Epub 2017 Mar 30. J Clin Pathol. 2017. PMID: 28360189 Free PMC article.

10

PD-1/PD-L1 inhibitors in haematological malignancies: update 2017.

Jelinek T, Mihalyova J, Kascak M, Duras J, Hajek R. Jelinek T, et al. Among authors: hajek r. Immunology. 2017 Nov;152(3):357-371. doi: 10.1111/imm.12788. Epub 2017 Aug 4. Immunology. 2017. PMID: 28685821 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

599 results

Search Page

Filters